Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pozen Continues Discussions with the FDA

By Drug Discovery Trends Editor | August 24, 2012

Pozen Inc. claims it is making progress in discussions with regulators about its experimental cardiovascular drug PA32540.

Pozen said the Food and Drug Administration appeared to be satisfied with the additional data it submitted in support of PA32540. Earlier this year, the FDA asked Pozen to do a study that would measure the bioequivalence of Pozen’s treatment compared to aspirin. The company said the FDA appears to be satisfied with its additional data even though it has not yet performed that study.

The FDA has not yet made a final determination on the additional data the company has submitted. The agency wants to confirm that PA32540 and aspirin show up in patients’ blood streams at similar rates after patients take the drugs.

The Chapel Hill, N.C., company also said it expects to file for approval of a lower-dose version of PA32540 in the first half of 2013. The FDA has agreed to give Pozen feedback as it prepares to make that filing. The lower-dose version is designated PA8140.

The drug is intended as an alternative to aspirin as a secondary treatment for the prevention of cardiovascular disease. Many people take aspirin to prevent heart problems, but long-term use of aspirin can cause ulcers. PA32540 contains aspirin and omeprazole, the active ingredient in heartburn drugs like Prilosec. The omeprazole is released as soon as the drug is taken and the aspirin is released over time.

PA32540 contains 325 milligrams of aspirin and 40 grams of omeprazole, and the company is now developing a version with 81 milligrams and aspirin and 40 milligrams of omeprazole. The FDA encouraged Pozen to study the lower-dose version and said it might only approve the larger-dose version for limited groups of patients.

Date: August 24, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50